3320 related articles for article (PubMed ID: 686614)
1. [Urinary evaluation of 5-S-cysteinyldopa and seric evaluation of IgG4 subclass during follow-up of 27 primitive malignant melanomas (author's transl)].
Cesarini JP; Daveau M; Picard F; Fournier E; Rivat L; Rivat C
Ann Dermatol Venereol; 1978 Apr; 105(4):405-8. PubMed ID: 686614
[TBL] [Abstract][Full Text] [Related]
2. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
[TBL] [Abstract][Full Text] [Related]
3. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
4. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
Paul E; Graef V; Ruppel R; Hellwich M
Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
[TBL] [Abstract][Full Text] [Related]
5. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
6. [Urinary 5-S-cysteinyldopa in malignant melanoma subjects-with special reference to melanoma stages and dopa loading test (author's transl)].
Ichihasi M; Mojamdar M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1981 Sep; 91(10):1045-9. PubMed ID: 6798247
[No Abstract] [Full Text] [Related]
7. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
8. [High-performance liquid chromatographic determination of urinary 5-S, 2-S-, 6-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa (author's transl)].
Morishima T; Saito M; Fujita M; Fukada E; Hanawa S
Nihon Hifuka Gakkai Zasshi; 1982 Jan; 92(1):53-6. PubMed ID: 6804671
[No Abstract] [Full Text] [Related]
9. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
10. [IgG levels in the sera of melanoma patients (author's transl)].
Daveau M; Pavie-Fischer J; Rivat L; Rivat C; Ropartz C; Peter HH; Cesarini JP; Kourilsky FM
Ann Dermatol Venereol; 1977; 104(6-7):458-60. PubMed ID: 921180
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of malignant melanoma with DTIC--therapeutic effects determined by 5-S-cysteinyldopa changes in the urine (proceedings)].
Agrup G; Hafström L; Jönsson PE; Rorsman H
Lakartidningen; 1978 Dec; 75(49):4599-600. PubMed ID: 364213
[No Abstract] [Full Text] [Related]
12. Free and bound 5-S-cysteinyldopa and dopa in human malignant melanomas.
Agrup G; Hansson C; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1978; 58(3):270-2. PubMed ID: 78645
[TBL] [Abstract][Full Text] [Related]
13. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of 5-S-cysteinyldopa monitoring in patients with malignant melanoma.
Bánfalvi T; Gilde K; Boldizsár M; Kremmer T
Neoplasma; 2002; 49(2):121-5. PubMed ID: 12088105
[TBL] [Abstract][Full Text] [Related]
15. Urinary free and conjugated 5-S-cysteinyldopa in normal subjects and in patients with melanoma.
Graef V; Paul E
Br J Dermatol; 1982 Jan; 106(1):53-7. PubMed ID: 6800394
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic evaluation of human malignant melanoma by urinary 5-S-cysteinyldopa dynamics: chemotherapy and surgery].
Inoi T; Mojamdar M; Ichihashi M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1984 Jan; 94(1):39-43. PubMed ID: 6433083
[No Abstract] [Full Text] [Related]
18. [Correlation of urinary 5-S-cysteinyldopa with repeated remission of melanoma induced by DTIC combination chemotherapy].
Inoi T; Mojamdar M; Ichihashi M; Mishima Y
Nihon Hifuka Gakkai Zasshi; 1982 Sep; 92(10):1065-9. PubMed ID: 6821170
[No Abstract] [Full Text] [Related]
19. Isolation of 2-S-cysteinyldopa and 2,5-S,S-dicysteinyldopa from the urine of patients with melanoma.
Prota G; Rorsman H; Rosengren AM; Rosengren E
Experientia; 1977 Jun; 33(6):720-1. PubMed ID: 891724
[No Abstract] [Full Text] [Related]
20. Melanin-related metabolites in urine of B16 melanoma-bearing mice.
Wakamatsu K; Ito S; Fujita K
Acta Derm Venereol; 1988; 68(5):385-9. PubMed ID: 2461020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
